Gly-Gly-Phe-Gly

Gly-Gly-Phe-Gly is a peptide spacer and can be applied to Doxorubicin (HY-15142A) (DXR) conjugates. Gly-Gly-Phe-Gly can be used as an ADC linker to synthesize ADCs, such as Puxitatug samrotecan (AZD 8205) (HY-171689) [1][2][3].

Product Specifications

CAS Number

[200427-88-9]

UNSPSC

12352209

Hazard Statement

H302, H315, H319

Target

ADC Linker; Drug Intermediate

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gly-gly-phe-gly.html

Purity

99.51

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NCC(NCC(N[C@H](C(NCC(O)=O)=O)CC1=CC=CC=C1)=O)=O

Molecular Formula

C15H20N4O5

Molecular Weight

336.34

Precautions

H302, H315, H319

References & Citations

[1]Shiose Y, et al. Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates. Bioconjug Chem. 2009 Jan;20 (1) :60-70.|[2]Kinneer K, et al. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clin Cancer Res. 2023 Mar 14;29 (6) :1086-1101.